Articles
-
All
-
Scientific Reviews
-
EDM
-
Blog
-
Most Recent
-
Oldest
-
SARS-CoV-2 contains four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. All the proteins and subcellular structures of CoVs are promising targets for SARS-CoV-2 research.
-
The concept of ADC can be traced back to the early 1900s, It is a visionary magic bullet that could deliver a toxic drug to certain malignant cells without affecting other normal tissues. Now, it seems that a golden age of ADC drug development is coming.
-
PROTAC, which exploit the ubiquitin-proteasome pathway to specifically degrade target proteins. PROTACs not only solve the problem of undruggability but they also have other advantages compared to traditional drug targeting strategies.
-
PROTAC — Target Selection and Design
2022-07-08
A PROTAC molecule consists of three components: a target protein binding ligand, an E3 ligase ligand, and a linker connecting these two moieties. Here, we will discuss the conventional approaches for the rational design of PROTAC molecules. -
Organoids represent an important bridge between 2D cultures and in vivo mouse/human models. The organoid technology exerts enormous potential in evaluation of efficacy and toxicity of drugs, regenerative medicine, and precision medicine.In this article, we will briefly introduce organoid technology.
-
Development of Intestinal Organoid
2022-07-28
3D organoid is one of the revolutionary developments in biomedical field during the past 10 years. The establishment of intestinal organoids is an important milestone in the development of organoid technology. -
BacPROTACs is composed of a POI ligand, a chemical linker and a ClpCNTD anchor. BacPROTACs can induce in vitro and in vivo degradation of non-eukaryotic proteins in bacteria without the ubiquitin proteasome system.
-
Organoids have great potential in research of organ development, disease modeling, drug screening and, precision and regenerative medicin. In this article, we will expalin the origin of the organoids. Adult stem cells (ASCs) or pluripotent stem cells (PSCs) , which is the better choice.
-
TME (Tumor microenvironment) is considered as a complex integrated system, composed of cellular components such as tumor cells and immune cells, as well as non-cellular components such as ECM and cytokines. According to the spatial distribution of immune cells in TME, "hot" and "cold" TME will be explained in this article.
-
The latest study of Cell magazine "Neural mechanism underlying depressive-like state associated with social status loss" considers social factors as a breakthrough point. It has been found that the downward transition of social status induces depression-like behavior in mice whereas improves the depressive state by restoring their social environment.
-
PROTAC - Design Strategy for Targeting
2023-04-23
Protein degradation targeting chimera (PROTAC) is a technology that uses the ubiquitin proteasome pathway to silent target protein. However, PROTAC still has problems such as solubility, membrane permeability, and selectivity. In this article, we have summarized three strategies for optimization: light-controlled linker, PAC molecule, and specific E3 ligase. -
Necroptosis, also known as necroptosis, is a form of regulated necrotizing cell death mediated by RIP1 and RIP3 kinases. Necroptosis is a process that prevents the self-destruction of activated cells that are blocked by apoptosis. Necroptosis plays a tumor suppressor role in most cases. It may provide benefits in the researches of a variety of human diseases involving immune inflammation and cell death.
-
Stem cell classification and its application
2023-05-18
Stem cells (SCs) have the unique ability to self-renew and differentiate into different cell types. SCs can differentiate into various types of tissue cells under specific conditions. Additionally, they can be further cultured to form different tissues and organs in the human body. Stem cells have numerous applications in various fields, including cell therapy, organ transplantation, neurodegenerative disease modeling, and drug screening. -
HLA-E, A Novel Immune Checkpoint
2023-06-29
Immune checkpoints have immunosuppressive functions. It can be used in the research of tumor immunotherapy. In this article, we introduce a new paper entitled "Immune checkpoint HLA-E: CD94 - NKG2Amediates evasion of circulating tumor cells from NK cell surveillance "research paper. -
Organoid Culture: Questions & Answers
2023-07-26
In the last issue, we conducted a live lecture on the theme of organoid culture. Today, we have a special topic to solve your doubts in the last live class! -
WHO's Q2 drug list has been updated. Let's take you through the list of the most noteworthy small molecule drugs that we should pay attention to.
-
FDA Approved Drug List!
2023-09-14
In the first half of 2023 (as of June 27), the FDA approved 26 new drugs, let's take you learn about it through the article. -
IHC is an indispensable technique for studying tissue morphology and in situ antigen expression, but usually only one or two antigens in tissues can be stained for analysis. It cannot judge the results more intuitively. Today, Little M will introduce you to the upgraded version mlHC.
-
A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening of diseases such as cancer, infectious diseases, and rare diseases.
-
FDA Annual Review | Record-breaking number of new drug approvals in 2023!
-
KRAS, a gene we've heard so much about, has quickly risen to fame after shedding its "undruggable" label. After reading numerous articles, it's easy to feel overwhelmed and wonder: What exactly should we know about this often-discussed but previously "undruggable" target KRAS?
-
Compound Screening Guide!
2024-03-15
How to use compound library? How to design an experiment if you buy a compound library? Want a specific experimental protocol? This article will introduce popular experimental techniques and provide new ideas for publishing high level literature. -
Wnt/β-catenin and tumor EMT
2024-03-18
Epithelial-Mesenchymal Transition (EMT) is closely related to the plasticity of tumor cells and is a necessary process for tumor metastasis. Wnt/β-catenin is one of the main actors involved in the EMT process. Today, we’re here to popularize the tumor EMT and Wnt/β-catenin pathway~ -
The 2024 AACR meeting concluded successfully in California, USA. Which antitumor drugs stole the show at this conference?
-
Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their groundbreaking work in nucleoside modification, which paved the way for the creation of successful mRNA vaccines to fight against COVID-19. Let's now delve into the complete process of mRNA vaccine development.
-
Science | A "new" mechanism for non-ubiquitinated Midnolin-proteasomal degradation pathway
2024-04-26
“ubiquitin-mediated protein degradation” won the Nobel Prize in Chemistry in 2004! In fact, proteasomes degrade not only ubiquitinated proteins but also non-ubiquitinated ones. The mechanism remains shrouded in mystery. After reading this piece today, you might have a lightbulb moment! -
Exosomes, which won the Nobel Prize in 2013, are still a research hotspot in the national natural sciences, and their popularity has only increased over the past decade (in 2022, they still rank 5th in the national natural sciences hotspots!). Why have exosomes become the darling of scientific research? Let's take a look together~
-
How important is the compound library? It connects to drug screening on one end and leads to lead compound modifications on the other, serving as one of the sources of new drug development.
-
Degrade target proteins through the autophagy-lysosome pathway including LYTAC, AUTAC, and ATTEC have gained increasing attention in recent years due to their significant research potential!
-
Antibodies!
2024-07-26
Today, We introduce antibodies for everyone! -
What Are Popular Anti-tumor Drug Targets?
2024-08-20
The rapid development of targeted anti-cancer drugs has spurred diverse research across various modalities. These include small molecules, monoclonal antibodies (mAbs), cell immunotherapies, antibody-drug conjugates (ADCs), and PROTACs (proteolysis targeting chimeras). -
Virtual Screening and New Uses for Old Drugs
2024-09-17
With the advancement of medical science, drug screening against various disease targets has become the fundamental strategy for drug development. Currently, computer-based virtual screening techniques are emerging in the field of new drug research due to their efficiency and low cost. Let's explore it today! -
2024 Nobel Prize Announcements! Curious about the details? Click to dive into the exciting developments!
-
A New Form of Cell Death: PANoptosis!
-
We are thrilled to share the latest advancements in AI technology as highlighted in this insightful article. From groundbreaking innovations to transformative applications, the future of AI is brighter than ever!
-
Advancing Chronic Kidney Disease Research with GJ103 and Lamin B1 Antibody!
-
When you hear "inflammation" and "DNA damage," you might immediately think of disease or injury. However, in brains, these two processes are key steps in forming long-term memories, particularly related to specialized cells in our brain called hippocampal neurons.
-
This article will tell you about the common methods of modeling liver disease in animal models.
-
nside cells, the homeostasis and degradation of proteins is a precisely regulated process. If proteins cannot be degraded in time, it may lead to the occurrence of various diseases such as neurodegenerative diseases and cancer. This article will tell you the process of how proteins are recognized, labeled and then degraded!
-
This article will walk you through the remarkable impacts of anti-payload antibodies, delving into how these molecules are revolutionizing drug development and biological research!
-
This article introduces some common cardiovascular disease models, inducers, modeling protocols and successful modeling cases in the research.
-
Cell Migration vs. Invasion: Differences Revealed by Scratch Assays and Transwell Experiments
2025-05-30
In scientific research, cell migration and invasion are crucial for understanding many important biological processes. This article delves into commonly used detection methods: the scratch assay and Transwell migration/invasion assay. -
How should drug screening experiments be conducted? How can we ensure the accuracy of the lead compounds identified? This article will take you through how MCE's clients conduct drug screening experiments.
-
IHC, ICC, IF Techniques: A Practical Guide
2025-07-25
Confused About IHC/ICC/IF? Why Does Immunostaining Seem So Complicated? Read This Now! Master Immunostaining with Confidence! -
HTS Breakthroughs Powered by MCE Libraries
2025-08-13
Key High-Throughput Screening Breakthroughs of 2024 Featuring MCE -
Encountering challenges with the high costs and long timelines of drug screening? Have a defined target but remain uncertain how to efficiently identify active molecules? Unsure how to validate hits generated from virtual screening? The ‘Winning Combination’ of drug screening offers a powerful solution to address these critical obstacles.
-
A groundbreaking study in Nature Communications reveals the key mechanism behind Idiopathic Pulmonary Fibrosis and identifies an existing drug with the potential to counter it.
-
This detailed guide outlines the standardized experimental protocols for multiplex immunohistochemistry (mIHC), systematically summarizes common technical issues encountered during sample preparation, staining and imaging processes, and provides practical troubleshooting solutions to ensure reliable and reproducible results in biomedical research and clinical sample analysis.
-
Microglia– the only immune cells within the brain parenchyma. With advancements in imaging technologies, people’s understanding of microglia has shifted from being viewed as 'resting' cells to 'highly active' cells, particularly due to their dynamic processes that seem to be probing surrounding tissues and monitoring neuronal activity. This has made microglia a focal point of research in the field of neuroscience.
-
Exosomes—natural nanoscale carriers—are revolutionizing targeted therapy. This article uncovers the science behind their precision in drug delivery.
-
Cracking the PROTAC Permeability Barrier: CD36-Mediated Endocytosis as a Potential Breakthrough
2025-12-03
This article provides an in-depth analysis of cutting-edge literature revealing CD36 as a key mediator of cellular uptake for PROTACs and bRO5 compounds. By structurally optimizing PROTAC molecules to enhance their affinity for CD36, membrane permeability can be markedly improved, leading to significantly enhanced antitumor efficacy. -
Efficient Generation of Mouse Small Intestinal Organoids: A Complete Experimental Protocol Guide
2025-12-10
How to successfully create mouse small intestine organoids? A detailed, hands-on guide to the entire process, all in one article! -
This paper elaborates on cytokines for culturing major immune cells, their regulatory roles, recombinant cytokines' merits and MCE’s related high-quality products.
-
This article walks you through the experimental design and workflow of flow cytometry, delivering a clear, dynamic, and professional overview to elevate your research.
-
Molecular glue degraders have evolved from a serendipitous observation to one of the most dynamic and transformative fields in biomedical research.
-
Targeting the ‘Undruggable’ with PROTACs
2025-06-18
This review introduces the fundamental principles and mechanisms of PROTACs, highlights recent advances in molecular design and clinical development, and discusses emerging opportunities and remaining challenges in targeted protein degradation. -
This review critically examines the role of the JAK-STAT pathway in immunity and autoimmune diseases, reviews current clinical applications of targeted therapies, and highlights emerging trends in autoimmune drug development.
-
This review presents an overview of antibody–drug conjugates from design principles and antitumor mechanisms to structural innovations, clinical progress, and future development prospects.
-
This review summarizes the mechanisms of DSS-induced colitis, commonly used modeling approaches, and key considerations related to DSS molecular weight.
-
This review explores mechanisms and strategies for modulating the gut microbiota to enhance cancer immunotherapy, providing insights to improve therapeutic efficacy.
-
Combating Immune Evasion in Cancer
2025-10-15
This review summarizes the mechanisms by which tumors evade immune surveillance and discusses therapeutic strategies to restore antitumor immunity. -
This review outlines macrophage functions and classification, and provides practical experimental guidelines for macrophage differentiation, polarization, and identification.
-
Understanding In Vivo CAR-T Cell Therapy
2026-01-22
This review provides a comprehensive overview of in vivo CAR-T therapy, covering technical platforms, clinical translation, and key challenges such as gene delivery and immunogenicity. -
Highlight the overview of engineered EVs, their construction methods, and applications in cancer immunotherapy.
-
Explore ADC evolution, immune combination strategies, and clinical advances at the intersection of targeted therapy and immunotherapy.
-
Summarize LLPS principles, regulatory mechanisms, experimental strategies, and pathological roles to inspire mechanism-driven research and translational applications.
-
Tumor Organoid-Immune Cell Co-Culture Models: Advances, Applications, and Future Directions
2026-05-07
Summarize technical strategies, application advances, and future directions of tumor organoid–immune co-culture systems. -
Review mechanisms, major challenges, and efficacy-enhancing strategies of TCR-T therapy in solid tumors, with implications for future research and clinical translation.
-
Review the mechanisms, mitochondrial regulation, disease relevance, and translational opportunities of the NLRP3–STING axis in neuroinflammation.
-
Breaking Immune Resistance in Colorectal Cancer: From Molecular Mechanisms to Precision Therapy
2026-06-25
Explore CRC molecular subtypes, immune landscapes, resistance mechanisms, and emerging precision strategies for improving outcomes across distinct subtypes. -
Explore the mechanisms driving immune tolerance breakdown in autoimmune diseases and emerging tolerance-restoring strategies, with a focus on IL-2-based immune modulation.
-
Review the evolution of molecular glues from serendipitous discovery to rational design, highlighting how emerging targets and advances in screening, proteomics, structural biology, and AI are expanding the druggable proteome.
-
Explore the mechanisms of tumor immune evasion, dynamic checkpoint regulation, and the evolution of mechanism-driven combinations and patient stratification.
-
Explore how mitochondrial quality control, inflammatory signaling, and metabolic–epigenetic reprogramming regulate cellular senescence and the SASP, along with strategies to restore mitochondrial homeostasis.
-
R916562, a dual Axl/VEGF-R2 inhibitor, could be a potential anti-angiogenic and anti-metastatic drug for cancer chemotherapy.
-
Role of PRMT7 Probe SGC3027 in Cancer
2019-03-27
SGC3027 is the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is also a pro-drug, which converts to the active compound SGC8158 -
Alofanib, An Allosteric Inhibitor of FGFR2
2019-03-28
Alofanib is an allosteric inhibitor of FGFR2 and inhibits FGF-mediated proliferation with GI50s of 16-370 nM, showing pronounced antitumor activity. -
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with anti-tumor activity in acute leukemia and breast cancer cell lines.
-
A Lead PROTAC BRD9 Chemical Degrader
2019-04-06
PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader and a selective probe useful for the study of BAF complex biology. -
HS-1371 is a Small Molecule RIP3 Inhibitor
2019-04-09
HS-1371 is a novel kinase inhibitor of RIP3-mediated necroptosis, showing an inhibitory effect on S227 auto-phosphorylation of RIP3 at the basal level. -
MK-0429 is An Oral Integrin (αvβ3) Inhibitor
2019-04-11
MK-0429, an orally active αvβ3 inhibitor, is a potential therapeutic agent for the prevention of kidney fibrosis, melanoma and osteoporosis. -
Erteberel is a Selective ERβ Agonist
2019-04-16
Erteberel (LY500307) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and under development for the treatment of schizophrenia. -
MBQ-167 is a dual Rac/Cdc42 inhibitor in in metastatic cancer, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
-
PRN1008 is a Reversible Covalent and Oral Active Inhibitor of Bruton’s Tyrosine Kinase (BTK)
2019-04-18
PRN1008 is a selective, reversible covalent and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. -
Multiple Tyrosine Kinases Inhibitor TAS-115
2019-04-19
TAS-115 is a potent VEGFR and c-Met/HGFR-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
Y06036 is a potent and selective BET inhibitor for potential treatment of castration-resistant prostate cancer. With nanomolar inhibition.
-
JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.
-
TAK-828F is a potent, selective and orally active retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist. TAK-828F inhibits IL-17A cytokine expression and reduces symptoms of autoimmune encephalomyelitis mice.
-
Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.
-
NRX-252262 is a β-catenin:β-TrCP interaction enhancer, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM
-
TAK-981 is a selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities
-
TD-428 is a Highly Specific BRD4 Degrader
2019-04-29
TD-428, a immunomodulatory drug analog, is a highly specific BRD4 degrader with a DC50 of 0.32 nM. TD-428 reduces c-Myc levels more efficiently than JQ1. -
CB-6644 is a selective non-ATP-competitive inhibitor of the RUVBL1/2 complex. CB-6644 significantly reduces tumor growth without obvious toxicity.
-
A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM. Effective in inhibiting many cancer cell lines proliferation
-
NSC 228155 is a activator of EGFR and a potent inhibitor of KIX-KID interaction. NSC 228155 shows excellent anti-tumor activity.
-
MM-589 is an inhibitor of WDR5 and MLL protein-protein interaction. Binds to WDR5 (IC50=0.90 nM) and inhibits the MLL H3K4 methyltransferase activity.
-
USL311 is a selective CXCR4 antagonist, which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. Anti-tumor activity.
-
JI051 is a stabilizer for the Hes1-PHB2 interaction, induces cell-cycle arrest by inhibiting the Notch downstream effector gene Hes1.
-
IWP-O1, a Highly Potent Porcupine Inhibitor, Functions by Preventing the Secretion of Wnt Proteins
2019-06-03
IWP-O1 is a Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 functions by preventing the secretion of Wnt proteins[ -
GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM. Potently blocks the TNF response and RIP1-dependent inflammatory cytokine MIP-1β production.
-
PF-06465469 is a Covalent Inhibitor of ITK
2019-06-08
PF-06465469 is a potent and covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 inhibits MEK1/2 or AKT phosphorylation. -
JMS-17-2 is a CX3CR1 Antagonist
2019-06-12
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. Has potential to treat cancers such as breast cancer. -
BAY-11-7082 inhibits the proliferation and induces the apoptosis of U266 cells through inhibiting NF-κB pathway. BAY 11-7082 ameliorates experimental diabetic neuropathy by modulating neuroinflammation and improving antioxidant defence.
-
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt). S18-000003 ameliorates psoriasis-like lesions in vivo. S18-000003 can be used for the research of skin inflammatory diseases.
-
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3). AMG 487 has potential to treat metastatic cancer.
-
TPCA-1, a Direct Dual Inhibitor of STAT3 and NF-κB, Regresses Mutant EGFR-Associated NSCLC
2019-07-15
TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding. -
M-89 is a specific menin inhibitor, with a Kd of 1.4 nM. M-89 inhibits the Menin-MLL protein-protein interaction and has potential to treat MLL leukemia.
-
ACBI1 is a PROTAC Degrader of BAF Complex
2019-08-07
ACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2, SMARCA4 and PBRM1, with DC50s of 6 nM, 11 nM and 32 nM in MV-4-11 cells, respectively. -
MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions. MSX-122 has both anti-tumor and anti-metastasis activities.
-
MS31 is a highly selective spindlin 1 inhibitor, which inhibits the interactions between SPIN1 and H3K4me3. MS31 is not toxic to nontumorigenic cells.
-
WZ811 is an Orally Active CXCR4 Antagonist
2019-09-07
WZ811 is an orally active, highly potent competitive antagonist of CXCR4, which inhibits chronic lymphocytic leukemia progression and tumorigenesis. -
SGC-iMLLT is a potent, selective MLLT1/3-histone interactions inhibitor and shows high binding activity towards MLLT1 YEATS domain and MLLT3 YD.
-
RU-302 is a pan-TAM inhibitor that blocks the TAM Ig1 ectodomain and the Gas6 Lg domain interaction. RU-302 blocks Gas6-inducible Axl receptor activation.
-
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor and sensitizes apoptosis by in breast cancer.
-
BPK-29 disrupts the NR0B1 protein-protein interactions and impairs the anchorage-independent growth of KEAP1-mutant cancer cells.
-
NV03 is a potent and selective antagonist of UHRF1-H3K9me3 interaction by binding to UHRF1 TTD with a Kd of 2.4 μM and has anticancer activity.
-
sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer in a dose dependent manner with an IC50 of 1.8 μM.
-
BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (β2AR) with a dissociation constant Kd of 84 pM.
-
IACS-8803 is a highly potent cyclic dinucleotide stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
-
UK 356618 is a Selective MMP-3 Inhibitor
2019-12-25
UK 356618 is a selective and potent inhibitor of MMP-3. UK 356618 exhibits potent anti-inflammatory and anti-cancer activity. -
CH6953755 is a potent, orally active and selective YES1 kinase inhibitor leading to antitumor activity against YES1 Gene -amplified cancers.
-
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
2020-01-05
CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor. CA-4948 can be used for the treatment of lymphoma. -
BAY-985 is an orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 and IKKε, respectively.
-
ADH-503 is an orally active and allosteric CD11b agonist and leads to the repolarization of tumor-associated macrophages.
-
BI-9321 is a potent, selective and cellular active NSD3-PWWP1 domain antagonist, and specifically disrupts histone interactions of the NSD3-PWWP1 domain.
-
Balixafortide is a potent, selective peptidic CXCR4 antagonist with anti-cancer effects, and blocks β-arrestin recruitment and calcium flux.
-
SNDX-5613 is a potent, selective, small molecule inhibitor of the Menin-MLL binding interaction for targeted therapy in MLL-rearranged leukemias.
-
RBN-2397 is an orally active accross species NAD+ competitive inhibitor of PARP7. RBN-2397 binds to PARP7 and restores interferon (Type I) signaling.
-
MYCMI-6 is a selective MYC:MAX protein interactions inhibitor, which blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain.
-
TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with antitumor activity.
-
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
-
M-808 is a highly potent and efficacious covalent Menin-MLL interaction inhibitor. M-808 has a binding IC50 value of 2.6 nM.
-
MCP110 is an inhibitor of Ras/Raf-1 interaction in human cancer cells. The Ras family GTPases play a central role in the growth factor signaling.
-
CAY10404 is a potent and highly selective COX-2 inhibitor. CAY10404 is a potent inhibitor of PKB/Akt and MAPK signalling pathways.
-
MSA-2 is an orally available non-nucleotide STING agonist. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors.
-
CB-1158, a potent and orally bioavailable inhibitor of arginase, blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
-
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses effective anti-tumor activity in vitro and in vivo.
-
BC-LI-0186 is a selective inhibitor of LeuRS and RagD interaction (IC50=46.11 nM). BC-LI-0186 suppresses the activity of cancer-associated MTOR mutants.
-
GNE-371, a Chemical Probe for the Second Bromodomains of TFIID Subunit 1 and TFIID Subunit 1-Like
2020-12-09
GNE-371 is a selective chemical probe for the second bromodomains of human transcription-initiation-factor TFIID subunit 1 and TFIID subunit 1-like. -
BMS-P5 is an Orally Active PAD4 Inhibitor
2020-12-12
BMS-P5 is an orally active PAD4 inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model -
ML132, a potent and selective caspase 1 inhibitor with a unique selectivity pattern, is responsible for the proteolytic activation of IL-1β and IL-18.
-
WL47, a high-affinity cavolin-1 (CAV1) ligand (Kd=23 nM), act as a potent and selective disrupter of CAV1 oligomers.
-
CC-90001 is a potent, selective, and orally active inhibitor of JNK. CC-90001 can be used for the research of idiopathic pulmonary fibrosis (IPF).
-
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM).
-
L-Moses is the first potent, selective, and cell-active PCAF Brd inhibitor. L-Moses disrupts PCAF-Brd histone H3.3 interaction.
-
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist. SB-332235 inhibits acute and chronic models of arthritis in the rabbit.
-
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction. It induces high levels of IL-2.
-
MR837 is an Inhibitor of NSD2-PWWP1
2021-05-11
MR837 is a potent inhibitor of NSD2 (WHSC1)-PWWP1 protein-protein interaction. MR837 can bind with human NSD2. -
BI-3406 is a selective, orally bioavailable SOS1 inhibitor that binds to the catalytic domain of SOS1, preventing the interaction with KRAS.
-
PHT-7.3 is a Selective Inhibitor of Connector Enhancer of Kinase Suppressor of Ras 1 (Cnk1)
2021-05-27
PHT-7.3 is a selective inhibitor of Cnk1 pleckstrin homology (PH) domain. PHT 7.3 blocks the growth of mutant KRAS cells and tumors. -
Sitravatinib (MGCD516) is an Orally Bioavailable RTK Inhibitor with PD-1 Blockade Activity
2021-06-03
Sitravatinib, a small molecule RTK inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. -
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor and inhibits SIX1-mediated breast cancer metastasis.
-
EMD527040 is a highly selective αvβ6 antagonist with antifibrotic activities.
-
Lumiracoxib is a COX-2 inhibitor. Lumiracoxib acts as nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities.
-
Inupadenant is an orally active, highly selective A2A receptor antagonist with potent anti-tumor activity.
-
NRX-2663 is a potent enhancer of the interaction between β-catenin SCFβ-TrCP, potentiates the ubiquitylation of mutant β-Catenin by β-TrCP.
-
Ruxolitinib is a potent and selective JAK1/2 inhibitor and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy.
-
AZD4635 is a potent, selective and orally active antagonist of A2AR that reverses adenosine-mediated immune suppression.
-
IMD-0354 is a Selective IKKβ Inhibitor
2021-11-09
IMD-0354 is a selective IKKβ inhibitor and potently inhibits NF-κB activity. IMD0354 has antitumor activity. -
CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
-
Zingerone is a natural orally active nontoxic methoxyphenol potent anti-inflammatory, antidiabetic, antioxidize, and anti-tumor properties.
-
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
-
BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
-
Mirin is a potent MRN complex inhibitor. Mirin prevents MRN-dependent activation of ATM without affecting ATM protein kinase activity.
-
Gardiquimod is a TLR7/8 agonist and can inhibit HIV-1 infection.
-
Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
-
Pelecopan is a potent, selective, and orally active complement factor D inhibitor, possessing the potential to study paroxysmal nocturnal hemoglobinuria (PNH).
-
MS159 is a frist-In-class nuclear receptor binding SET NSD2 PROTAC degrader for multiple myeloma research.
-
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 has potent anti-cancer activity.
-
CAM 833, a potent and selective inhibitor of the BRCA2-RAD51 interaction, and has the potential for the cancer research.
-
Etrolizumab is a Gut-selective, Anti-β7 Integrin McAb for Inflammatory Bowel Disease (IBD) Research
2022-11-05
Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody and has the potential for the research of inflammatory bowel disease. -
Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer.
-
GN25 is a specific inhibitor of p53-Snail binding and shows anti-tumor effect against K-Ras-mutated cancer.
-
Mogamulizumab is an Anti-CCR4 monoclonal antibody. It enhances antibody-dependent cellular cytotoxicity and is effective against leukemia.
-
Bapotulimab (BAY-1905254) is an ILDR2 IgG antibody that blocks the immunosuppressive effects of ILDR2 on T-cell activation.
-
Nanrilkefusp alfa is a selective and strong IL-15 agonist. It inhibits tumor metastasis and viability by activating natural killer (NK) cells.
-
Urabrelimab (SRF231) is an anti-CD47 monoclonal antibody, blocking the CD47-SIRPα interaction. It has the potential to research anticancer.
-
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research
2023-02-07
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa can be used for glioblastoma research. -
Tifcemalimab, a Humanized anti-BTLA monoclonal antibody, blocks the interaction of HVEM-BTLA by binding to BTLA and activates lymphocytes.
-
Geptanolimab (CBT-501) is a programmed death-1 (PD-1) monoclonal antibody. Geptanolimab can be used in research forsolid tumor research.
-
Dazostinag is a STING Agonist and Can be used for Antibody-Drug Conjugates (ADCs) Synthesis
2023-03-13
Dazostinag is a STING agonist and a playload, to synthesis antibody-drug conjugates (ADCs). It has antitumor activity in vivo. -
Ruxolitinib is an orally-active JAK1/2 inhibitor. Ruxolitinib has the potential for the research of myeloproliferative neoplasm (MPN).
-
BBO-11818 is a potent, selective, orally bioavailable, and noncovalent pan-KRAS inhibitor targeting multiple clinically relevant KRAS mutants in both ON and OFF states.
Products
-
All
-
Inhibitors & Agonists
-
Isotope-Labeled Compounds
-
Fluorescent Dye
-
Peptides
-
Recombinant Proteins
-
Antibodies
-
Screening Libraries
-
Kits
-
Inhibitory Antibodies
-
Reference Standards
-
Induced Disease Models Products
-
GMP Small Molecules
-
Biochemical Assay Reagents
-
Natural Products
| Cat. No. | Product Name | Information | Application | Publication |
|---|---|---|---|---|
| HY-11109 | Resatorvid |
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
|
|
536
|
| HY-13417A | AICAR phosphate |
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Pain
Digestive System Inflammation
SARS-CoV-2 Infection
Obesity
Lung Fibrosis
|
231
|
|
| HY-100941 | CCCP |
CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
|
|
192
|
| HY-B2176 | ATP |
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
Source: widespread |
|
178
|
| HY-B0240 | Disulfiram |
Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu2+ increases intracellular ROS levels and induces cuproptosis.
|
Metabolic or Endocrine Disease
Breast Cancer
Prostate Cancer
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Depression
Pain
Autoimmune Disease
Digestive System Inflammation
SARS-CoV-2 Infection
|
161
|
| HY-100573 | Necrosulfonamide |
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
|
Mixed Lineage Kinase
Necroptosis
Pyroptosis
Caspase
NOD-like Receptor (NLR)
Keap1-Nrf2
TNF Receptor
Interleukin Related
NO Synthase
Heme Oxygenase (HO)
Digestive System Disease
Prostate Cancer
Leukemia/Lymphoma/Myeloma
Depression
Digestive System Inflammation
Cardiovascular Disease
Parkinson's Disease
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
147
|
| HY-B0141C | Estradiol hemihydrate |
Estradiol (β-Estradiol) hemihydrate is a steroid hormone and the major female sex hormone. Estradiol (β-Estradiol) hemihydrate can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol (β-Estradiol) hemihydrate can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering.
|
|
141
|
| HY-B0141 | Estradiol |
Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering.
|
Metabolic or Endocrine Disease
Prostate Cancer
Viral Infection
Bacterial Infection
Neurodegenerative Disease
Cardiovascular Disease
Luminal Breast Cancer
Metastatic Breast Cancer
SARS-CoV-2 Infection
|
141
|
| HY-L031 | Small Molecule Immuno-Oncology Compound Library |
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.
MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
|
|
88
|
| HY-14519 | Methotrexate |
Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
|
|
87
|
| HY-L008 | JAK/STAT Compound Library |
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).
MCE provides 738 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.
|
|
86
|
| HY-L075 | Anti-Lung Cancer Compound Library |
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.
As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.
MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
|
|
84
|
| HY-L079 | Anti-Blood Cancer Compound Library |
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.
Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.
MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
|
|
83
|
| HY-L131 | Osteogenesis Compound Library |
Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health.
Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc.
MCE offers a unique collection of 984 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.
|
|
83
|
| HY-L132 | Chemokine Compound Library |
Chemokines, or chemotactic cytokines, are small cytokines or signaling proteins secreted by cells. They are a component of intercellular communication, controlling the directional movement of immune cells especially leukocytes, as well as other cell types, for instance, endothelial and epithelial cells, which are essential to maintain human health and the function of the immune system.
The biological effects of chemokines are achieved by binding to chemokine receptors, which are G protein-coupled receptors found on the surface of leukocytes. Some chemokine receptors are involved in directing tumor metastasis and over-expression by certain tumors. So inhibiting the interaction between chemokine and chemokine receptors on the surface of tumor cells may be a new possible therapeutic approach. Some chemokine receptors are coreceptors for HIV entry, and related inhibitors have been approved by the FDA to treat patients with HIV. Obviously, chemokines and chemokine receptors have become new targets for studying cancer, HIV, inflammation, and other diseases.
MCE supplies a unique collection of 257 chemokine or chemokine receptor inhibitors and activators, all of which have the identified inhibitory or activated effect on chemokine or chemokine receptors. MCE Chemokine Library is a useful tool for drug research related to cancer, AIDS, and wound therapy.
|
|
83
|
| HY-L150 | Membrane Receptor-targeted Compound Library |
Membrane receptors, also known cell surface receptors or transmembrane receptors, are transmembrane proteins embedded into the plasma membrane which play an essential role in maintaining communication between the internal processes within the cell and various types of extracellular signals. They act in cell signaling by receiving (binding to) extracellular molecules, which are also called ligands. These extracellular molecules include hormones, cytokines, growth factors, neurotransmitters, lipophilic signaling molecules such as prostaglandins, and cell recognition molecules.
There are three kinds of membrane receptors: ion channel-linked receptors, enzyme-linked receptors and G-protein-linked receptors. They play important roles in keeping human normal physiologic processes. GPCRs and ion channels are important drug targets in drug discovery.
MCE provides a unique collection of 7,133 compounds targeting a variety of membrane receptors. MCE Membrane reeptor-targeted Compound Library can be used for membrane receptor-focused screening and drug discovery.
|
|
83
|
| HY-L156 | Autoimmune Disease Compound Library |
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).
MCE designs a unique collection of 1,040 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.
|
|
83
|
| HY-L161 | Cytokine Inhibitors Library |
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases.
MCE designs a unique collection of 1,416 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.
|
|
83
|
| HY-L175 | Inflammasomes related Compound Library |
Inflammasomes are classic pattern recognition receptors for natural immune responses. Inflammasomes are polymeric protein complexes that regulate inflammatory responses and pyrolytic cell death, thereby exerting the host's defense against microorganisms. Inflammasomes sensors are associated with adapter proteins, activating inflammatory caspase-1, releasing inflammatory cytokines and inducing cell death, endowing the host with defense against pathogens. NLRP1, NLRP3, NLRC4, AIM2, and pyrin are considered typical inflammasomes because they convert cysteine asparaginase-1 into catalytically active capsaicin-1. In addition to infectious diseases, the importance of inflammasomes is also related to various clinical diseases, such as autoimmune diseases, neurodegeneration and metabolic disorders, and the development of cancer. Therefore, it is necessary to strictly regulate the activation and function of inflammasomes to avoid accidental host tissue damage while inducing pathogens to kill the inflammatory response.
MCE designs a unique collection of 178 inflammasomes related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.
|
|
83
|
| HY-L185 | Anti-Fibrosis Compound Library |
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening.
MCE contains 2,568 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.
|
|
83
|
| HY-L194 | Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library |
Heat-clearing and detoxification is a specific treatment method in the research of traditional Chinese medicine (TCM), which is clinically used to treat infectious diseases with remarkable effect. Over the past decades, the research of heat-clearing and detoxification treatment has been one of the most active fields of combining traditional Chinese and western medicines, and has made remarkable achievements. Nowadays, the application field of heat-clearing and detoxification traditional Chinese medicine is not only limited to antibacterial and antiviral, but also has made progress in the research fields of anti-inflammatory reaction, anti-endotoxin, anti-peroxidative damage, anti-inflammatory cytokines, enhancement of immune function, protection of cellular organelles, and maintenance of calcium homeostasis. In addition to this, clearing heat and removing toxins has also made significant research progress in non-infectious diseases, for example, in tumors, cardiovascular diseases, renal diseases, blood diseases, geriatrics, and diabetes, all of which have shown good curative effect.
MCE can supply 1,282 monomer component from more than a hundred sources of heat-clearing and detoxification TCM, which can be used in TCM studies, drug development and mechanism-based studies.
|
|
83
|
| HY-L213 | Anti-Cancer Approved Drug Library |
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies.
This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment.
MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
|
|
83
|
| HY-L216 | Polysaccharides Compound Library |
Polysaccharides are long chains of carbohydrate molecules, consisting of multiple smaller monosaccharides. Polysaccharides are found mainly in natural sources such as plants, microorganisms, algae and animals. Polysaccharides have a large number of active functional groups, different chemical compositions and different molecular weight ranges, which determines their diversity in nature and structure. Also in the field of medical research, polysaccharides act as a class of functional compounds and thus play a role. For example, nanocarrier construction, immunomodulation and vaccine development, new strategies for antitumor therapy, tissue regeneration engineering applications and disease diagnosis. With the advancement of glycomics and synthetic biotechnology, human beings are moving from “knowing polysaccharides” to “designing polysaccharides”, which will provide innovative solutions for materials science, precision medicine and sustainable development.
MCE offers 70 polysaccharides that can be used in biomedical studies.
|
|
83
|
| HY-L258 | Alkyne Compound Library |
In modern medicinal chemistry and chemical biology research, alkyne (-C≡C-) structures play an important role in click chemistry, bioorthogonal labeling, and the construction of functional molecules due to their unique linear geometry and high reactivity. In particular, driven by the development of copper-catalyzed azide-alkyne cycloaddition (CuAAC) and copper-free click reactions (SPAAC), terminal alkyne groups have become important “chemical handles” for building complex biomolecular systems.
The MCE Alkyne Compound Library contains 437 compounds designed for the construction of click chemistry reaction systems and the development of diverse functional molecules. In drug discovery, these structures serve as key reactive sites that can efficiently undergo click reactions with azide groups, enabling modular assembly of PROTAC molecules, construction of ADC linkers, and rapid synthesis of bioorthogonal labeling probes. In addition, alkyne groups exhibit high stability, mild reaction conditions, and excellent biocompatibility, allowing them to maintain reactivity in complex biological environments. This contributes to improved efficiency and controllability in drug development, making them indispensable chemical building blocks in modern drug design and functional molecular engineering.
|
|
83
|
| HY-L937 | Unnatural Amino Acids Fragment library |
Unnatural amino acids (UAAs), also referred to as non-canonical amino acids (ncAAs) or non-proteinogenic amino acids, are a class of amino acids that are distinct from the 20 standard natural amino acids. They can be obtained through chemical synthesis, biosynthesis, and other approaches, with structural diversity far exceeding that of natural amino acids. UAAs are mainly including naturally occurring non-canonical amino acids, chemically synthesized amino acids, and biosynthetic amino acids, which provide a molecular basis for protein function design.
UAAs exhibit significant value in multiple fields. They can optimize the pharmacokinetic properties of peptide drugs and peptidomimetics, modify enzyme functions and endow them with new biological activities, thereby overcoming the limitations of traditional peptide drugs and expanding the chemical space . Meanwhile, UAAs can serve as molecular probes to analyze protein-protein interactions and investigate the regulatory mechanisms of protein functions.
MCE has compiled a UAAs Fragment Library comprising nearly a thousand unnatural amino acid fragments with extensive coverage of chemical space and enhanced structural diversity. This compound library can be widely applied in peptide synthesis, drug design, and protein engineering.
|
|
83
|
| HY-L948 | PD-1/PD-L1 Lead-like Library |
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy.
A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity.
Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.
|
|
83
|
| HY-10964 | Vadimezan |
|
80
|
|
| HY-N0822 | Shikonin |
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Depression
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
74
|
| HY-107202 | Polyinosinic-polycytidylic acid |
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
|
RIG-I-like receptor (RLR)
Toll-like Receptor (TLR)
PKD
HSP
Bcl-2 Family
Interleukin Related
Apoptosis
Infection
Digestive System Disease
Prostate Cancer
Pain
Digestive System Inflammation
Lung Fibrosis
Rheumatoid Arthritis
|
73
|
| HY-A0003 | Lenalidomide |
Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8+ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury.
|
Molecular Glues
Ligands for E3 Ligase
IKZF Family
Casein Kinase
Apoptosis
Pyroptosis
MDM-2/p53
TNF Receptor
Inflammation or Immune System Disease
Renal Disease
Chronic Lymphocytic Leukemia
Diffuse Large B-cell Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Liver Failure
|
63
|
| HY-108841 | Raleukin |
Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction.
Species: Human |
|
57
|
| HY-B1081A | Oxidopamine hydrobromide |
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
|
Dopamine Receptor
Autophagy
Mitophagy
COX
PGE synthase
Interleukin Related
p38 MAPK
Apoptosis
Caspase
|
50
|
| HY-100564A | 2',3'-cGAMP sodium |
2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP sodium binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm.
|
|
44
|
| HY-100564 | 2',3'-cGAMP |
2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm.
|
|
44
|
| HY-117287 | Deucravacitinib |
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
|
|
36
|
| HY-N0182 | Fisetin |
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
|
Digestive System Disease
Prostate Cancer
Viral Infection
Depression
Digestive System Inflammation
SARS-CoV-2 Infection
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
35
|
| HY-B2247 | PLGA (50:50) |
PLGA (50:50) (poly(lactic-co-glycolic acid) (50:50)) is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA) which can be used to fabricate devices for drug delivery and tissue engineering applications.
|
|
32
|
| HY-P9970 | Infliximab |
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
The component ratio of this product is Active ingredient : Excipients = 9 : 47. Species: Human |
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
Lung Cancer
Breast Cancer
|
30
|
| HY-P9908 | Adalimumab |
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
Species: Human |
|
20
|
| HY-134581 | Enpatoran |
Enpatoran (M5049) is an orally active and selective TLR7/8 antagonist. Enpatoran inhibits the activation of the downstream type I interferon pathway. Enpatoran is used in studies of cutaneous lupus erythematosus, systemic lupus erythematosus with cutaneous manifestations, and psoriasis.
|
|
18
|
| HY-108847 | Etanercept |
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
|
|
16
|
| HY-P1860 | TNF-α (31-45), human |
|
13
|
|
| HY-P9926 | Dupilumab |
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.
Species: Human |
Inflammation or Immune System Disease
Breast Cancer
Non-Small Cell Lung Cancer
Staphylococcus Aureus Infection
|
9
|
| HY-107632 | GYY4137 |
GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
|
8
|
| HY-147124 | RIG012 |
RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.
|
|
6
|
| HY-W250978 | Ovalbumins |
Ovalbumins are the major proteins in egg white. Ovalbumins act as an allergen and inducer, and can be applied to mouse models of allergic diseases. Ovalbumins can induce allergic rhinitis in mice via sensitization and nasal challenge. Ovalbumins can be used to establish asthma models.
Ovalbumin, low endotoxin (HY-W250978A) is recommended for model establishment. |
|
6
|
| HY-P99168 | Anifrolumab |
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.
Species: Human |
|
5
|
| HY-N0474 | Tyrosol |
Tyrosol is a derivative of phenethyl alcohol. Tyrosol attenuates pro-inflammatory cytokines from cultured astrocytes and NF-κB activation. Anti-oxidative and anti-inflammatory effects.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
|
4
|
| HY-N0609 | Cinnamaldehyde |
Cinnamaldehyde is a major and a bioactive compound isolated from the leaves of Cinnamomum osmophloeum kaneh. Cinnamaldehyde is a cytokine production inhibitor. Cinnamaldehyde has anti-bacteria, anti-oxidation, and anti-inflammatory properties.
|
|
3
|
| HY-Y0344J | Sodium chloride, for molecular biology |
Sodium chloride is an orally active salt. Sodium chloride induces the expression of ATP1A1. Sodium chloride induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride drives autoimmune disease by the induction of pathogenic Th17 cells.
|
|
3
|
| HY-Y0344D | Sodium chloride, for cell culture |
Sodium chloride, for cell culture is an orally active salt. Sodium chloride, for cell culture induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, for cell culture enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, for cell culture drives autoimmune disease by the induction of pathogenic Th17 cells.
|
Small Cell Lung Cancer
Experimental Autoimmune Encephalomyelitis
Experimental Autoimmune Encephalomyelitis
|
3
|
| HY-P990034 | Pateclizumab |
Pateclizumab (MLTA3698A) is a humanized antibody against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis.
Species: Human |
|
2
|
| HY-P99008 | Atibuclimab |
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury.
Species: Human |
Inflammation or Immune System Disease
Pulmonary Disease
SARS-CoV-2 Infection
Amyotrophic Lateral Sclerosis
|
2
|
| HY-B0141R | Estradiol (Standard) |
Estradiol (Standard) is the analytical standard of Estradiol. This product is intended for research and analytical applications. Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering.
|
|
2
|
| HY-P72907 | CD40L/CD154/TRAP Protein, Human (His) |
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in human, cleaved into 2 chains of membrane form (1-261 a.a.) and soluble form (113-261 a.a.) which serves as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). CD40L/CD154/TRAP Protein, Human (His) has a total length of 144 amino acids (E108-L261), is expressed in E. coli cells with C-terminal His-tag.
Species: Human; Source: E. coli |
|
2
|
| HY-13740S | Resiquimod-d5 |
Resiquimod-d5 is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
|
|
1
|
| HY-P99342 | Imdevimab |
Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins.
Species: Virus |
|
1
|
| HY-N2083 | Handelin |
Handelin is a guaianolide dimer from Chrysanthemum boreale that has potent anti-inflammatory activity by down-regulating NF-κB signaling and pro-inflammatory cytokine production.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
|
1
|
| HY-P990007 | Tulisokibart |
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis.
Species: Human |
|
1
|
| HY-13417S | AICAR-13C2,15N |
AICAR-13C2,15N (Acadesine-13C2,15N; AICA Riboside-13C2,15N) is the 13C and 15N labeled AICAR (HY-13417). AICAR (Acadesine) is an adenosine analog and a AMPK activator. AICAR regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR is also an autophagy, YAP and mitophagy inhibitor.
|
|
/
|
| HY-P1796A | Gp100 (619-627) acetate |
Gp100 (619-627) acetate is amino acids 619 to 627 fragment of human melanoma antigen glycoprotein 100 (gp100). Gp100 has been a widely studied target for melanoma immunotherapy.
|
|
/
|
| HY-143686 | ImmTher |
ImmTher is a liposome-encapsulated lipophilic disaccharide tripeptide derivative of muramyl dipeptide. ImmTher can up-regulate specific monocyte cytokine genes and activate monocyte-mediated tumoricidal activity.
|
|
/
|
| HY-B0174AS3 | Olsalazine-d6 |
Olsalazine-d6 is the deuterium labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.
|
|
/
|
| HY-B0966S | Dioxybenzone-d3 |
Dioxybenzone-d3 is deuterium labeled Dioxybenzone. Dioxybenzone (Benzophenone-8; UV-24) is an organic compound used to block UVB and short-wave UVA (ultraviolet) radiation. Dioxybenzone has orally activity. Dioxybenzone exhibits estrogenic disrupting effect. Dioxybenzone up-regulates inflammatory cytokines. Dioxybenzone can be used for cancer, reproductive system disease and inflammatory disease study.
|
|
/
|
| HY-B0174AS | Olsalazine-13C6 |
Olsalazine-13C6 is the 13C labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.
|
|
/
|
| HY-P1796 | Gp100 (619-627) |
Gp100 (619-627) is amino acids 619 to 627 fragment of human melanoma antigen glycoprotein 100 (gp100). Gp100 has been a widely studied target for melanoma immunotherapy.
|
|
/
|
| HY-P990083A | Tegoprubart (powder) |
Tegoprubart (powder) (AT-1501 (powder)) is a CD40 ligand inhibitor (EC50=100 ng/mL) and immunosuppressant that selectively inhibits the CD40 ligand, a co-stimulatory molecule involved in T cell activation. Tegoprubart (powder) suppresses immune rejection, prevents rejection in animal transplantation models, and reduces cell-mediated and antibody-mediated immune responses to create a more immunotolerant environment. Tegoprubart (powder) preserves renal function when combined with Mycophenolate (HY-B0421) and Corticosteroids, and maintains graft function in preclinical studies. Tegoprubart (powder) is applicable to research related to kidney transplantation and kidney transplant rejection.
|
|
/
|
| HY-P3728 | Interleukin II (60-70) |
Interleukin II (60-70) is a 60-70 fragment of the cytokine Interleukin II polypeptide.
|
|
/
|
| HY-N3487 | Isodorsmanin A |
|
/
|
|
| HY-P11253 | DOTA-Bn-CA-170 |
DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a Kd value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [68Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy.
|
|
/
|
| HY-19717S | DCVC-13C3,15N |
DCVC-13C3,15N is 15N and 13C labeled DCVC. DCVC (S-[(1E)-1,2-Dichloroethenyl]-L-cysteine) is a bioactive metabolite of trichloroethylene (TCE). DCVC inhibits pathogen-stimulated pro-inflammatory cytokines IL-1β, IL-8, and TNF-α release from tissue cultures.
|
|
/
|
| HY-NP077A | Phaseolus vulgaris Lectin-P |
Phaseolus vulgaris Lectin-P is the protein form of Phytohemagglutinin before the separation and purification of Phytohemagglutinin-L (PHA-L) and PHA-E. Phaseolus vulgaris Lectin-P can be used to stimulate the proliferation of peripheral mononuclear cells, promote the production of certain cytokines and the expression of membrane surface proteins.
|
|
/
|
| HY-P992342 | DCB-8 |
|
/
|
|
| HY-P1828 | EGFRvIII peptide (PEPvIII) |
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy.
|
|
/
|
| HY-P4054 | IEIK 13 |
IEIK 13 is a self-assembling peptide (SAP) sequence. IEIK 13 can be used for the research of cartilage tissue engineering
|
|
/
|
| HY-P10293 | NQEQVSP |
NQEQVSP, a fibrin-binding protein-derived peptide (FBP), is a factor XIIIa substrate. NQEQVSP can be recognized by factor XIII and is enzymatically conjugated into fibrin during polymerization.
|
|
/
|
| HY-NP077B | Phaseolus vulgaris Lectin-M |
Phaseolus vulgaris Lectin-M is a sticky protein form of lectin. Phaseolus vulgaris Lectin-M is mainly used to stimulate the proliferation of peripheral mononuclear cells, promote the production of certain cytokines and the expression of membrane surface proteins 。
|
|
/
|
| HY-P992518 | Pumitamig (Mouse IgG2a) |
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
|
|
/
|
| HY-P992061 | Anti-Mouse CD3E Antibody (500A2) |
Anti-Mouse CD3E Antibody (500A2) is an antibody targeting mouse CD3ε, which specifically binds to the region on CD3ε adjacent to the T cell receptor binding site. Anti-Mouse CD3E Antibody (500A2) triggers functional signal transduction in immature T cells and activates naive T cells. When cross-linked, Anti-Mouse CD3E Antibody (500A2) induces a rapid, robust and transient increase in cytoplasmic calcium concentration, acting as a potent calcium flux inducer. Anti-Mouse CD3E Antibody (500A2) is suitable for multiple experimental techniques such as flow cytometry, immunoprecipitation and EMARS reactions. It can be used to detect CD3E expression on thymocytes, mature T lymphocytes and NK-T cells from different mouse strains, or to identify membrane cluster components of the TCR complex, and shows no cross-reactivity with rat leukocytes.
Species: Mouse |
|
/
|
| HY-B2162H | Chondroitin sulfate (from fish) |
Chondroitin sulfate (from fish), one of five classes of glycosaminoglycans, has been widely used in the treatment of osteoarthritis. Chondroitin sulfate (from fish) reduces inflammation mediators and the apoptotic process and is able to reduce protein production of inflammatory cytokines, iNOS and MMPs.
|
|
/
|
| HY-149773S | HPK1-IN-40-d2 |
HPK1-IN-40 (compound 49) is a potent and selective HPK1 inhibitor with an IC50 of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity.
|
|
/
|
| HY-P992051 | Anti-CD103 Antibody (hCD103.01A) |
Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
/
|
| HY-16900G | Rolipram (GMP) |
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis.
|
|
/
|
| HY-P991529 | AGEN-2373 |
AGEN-2373 is a conditionally active agonist antibody targeting the co-stimulatory receptor CD137. GEN-2373 binds to CD137 without disruption of ligand binding. AGEN-2373 stimulates CD137 under receptor clustering conditions. AGEN-2373 can enhance T cell activity when combined with other checkpoint modulators (e.g. PD-1 antagonist and OX40 agonist). AGEN-2373 can be studied in research for human malignancies.
Species: Human |
|
/
|
| HY-P11355 | KRAS WT Peptide |
KRAS WT Peptide is the normal sequence peptide of the Kirsten rat sarcoma virus (KRAS) gene without oncogenic mutations. KRAS WT Peptide can be used for the study of evaluating the specificity and safety of KRAS-targeted immunotherapies.
|
|
/
|
| HY-101112 | Okicenone |
|
/
|
|
| HY-P3831 | β-Interleukin II (44-56) |
β-Interleukin II (44-56) is a 44-56 fragment of beta-interleukin II polypeptide. Interleukin family are a group of cytokines associated with immune system, mainly expressed by leukocytes.
|
|
/
|
| HY-P10432 | SHAAGtide |
SHAAGtide is a FPRL1 activator. SHAAGtide has anti-inflammatory activity, mediates its biological activity via FPR2 and is used to reduce the expression of inflammatory cytokines in mouse models. SHAAGtide can be used in the study of diseases such as lung inflammation and fibrosis.
|
|
/
|
| HY-P0071 | F 991 |
F 991 is an immunoglobulin free light chain antagonist. F 991 can significantly reduce the levels of pro-inflammatory cytokines (TNF-α and IL-6). F 991 can be used for research on allergic conditions.
|
|
/
|
| HY-10978S | Crisaborole-d4 |
|
/
|
|
| HY-P11296 | LLVK |
LLVK is a selective IκB phosphorylation inhibitor. LLVK reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). LLVK is promising for research of inflammatory bowel disease and rheumatoid arthritis.
|
|
/
|
| HY-N3788 | Dulcioic acid |
Dulcioic acid (compound 19) is a product isolated from Tripterygium wilfordii Hook f. Dulcioic acid shows a significant inhibitory effect on cytokine production.
|
|
/
|
| HY-P991557 | ABI793 |
|
/
|
|
| HY-P991634 | IBI-325 |
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.
Species: Human |
|
/
|
| HY-116705G | 2-Deoxy-2-fluoro-L-fucose (GMP) |
2-Deoxy-2-fluoro-L-fucose (2-Fluorofucose) GMP is a fucosyltransferase inhibitor that inhibits core fucosylation modification in cells. 2-Deoxy-2-fluoro-L-fucose GMP promotes the production of defucosylated IgG1 antibodies in IgG1-expressing cell culture systems; it regulates the levels of inflammatory cytokines such as IL-1β, IL-6 and TGF-β in human induced pluripotent stem cell-derived microglia. 2-Deoxy-2-fluoro-L-fucose GMP can be used in the research of related diseases including dengue fever and Alzheimer's disease.
|
|
/
|
| HY-P10417 | RTDLDSLRTYTL |
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development.
|
|
/
|
| HY-P5350 | FN-A208 fusion peptide |
FN-A208 is a biological active peptide. (This peptide is a fusion of A208, derived from murine laminin a1, and the active site of fibronectin (GRGDS), with a glycine spacer. This peptide forms amyloid-like fibrils and promotes formation of actin stress fibers that mediate fibroblast cell attachment, offering it potential as a bioadhesive for tissue regeneration and engineering. FN-A208 interacts with IKVAV receptors and integrins. Its activity is disrupted by the presence of EDTA.)
|
|
/
|
| HY-P991654 | SAR228810 |
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research.
Species: Human |
|
/
|
| HY-P2642 | Peptide 78 |
Peptide 78, a chemotactic cytokine, a 78 amino acid protein member of the IL-8 or C-X-C chemokine supergene family. ENA-78 plays an important role in the elicitation of predominantly neutrophils (PMNs) into the joints of rheumatoid arthritis (RA).
|
|
/
|
| HY-P992182 | ANB032 |
ANB032 is a human IgG4 kappa BTLA agonist monoclonal antibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines. ANB032 can be used for the research of atopic dermatitis[1].
Species: Human |
|
/
|
| HY-177130S | Socrodeucitinib |
Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC50 value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases.
|
|
/
|
| HY-D3190 | BODIPY−DOX |
BODIPY-DOX is a conjugate composed of BODIPY and Doxorubicin (HY-15142A), as well as a pH-activated fluorescent probe for M1 macrophages and an apoptosis inducer. BODIPY-DOX undergoes pH-induced hydrazone bond cleavage in acidic M1 macrophage phagosomes, thereby releasing cytotoxic Doxorubicin (Dox) and inhibiting the function of pro-inflammatory M1 macrophages. BODIPY-DOX highly selectively inhibits the production of relevant pro-inflammatory cytokines by mouse and human monocyte-derived M1 macrophages, while exerting minimal effects on M2 or unactivated macrophages. Therefore, BODIPY-DOX enables simultaneous fluorescent tracing, differentiation and elimination of specific macrophage subsets, and exhibits the potential to regulate tissue regeneration in zebrafish models.
|
|
/
|
| HY-P3912 | Endotoxin inhibitor |
Endotoxin inhibitor a synthetic peptide that binds lipid A with high affinity, thereby detoxifying LPS (HY-D1056) and preventing LPS-induced cytokine release in vivo. Endotoxin inhibitor inhibits the febrile response to LPS with very low toxicity and lethality.
|
|
/
|
| HY-D2630 | Cy3 HA MA (MW 3000) |
Cy3 HA MA (MW 3000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 3000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
|
|
/
|
| HY-N15322 | Polyandric acid A |
Polyandric acid A is a clerodane diterpenoid that can be isolated from the Australian medicinal plant D. polyandra. Polyandric acid A attenuates pro-inflammatory cytokine secretion.
|
|
/
|
| HY-W013021R | Norbornene (Standard) |
Norbornene (Standard) is the analytical standard of Norbornene (HY-W013021). This product is intended for research and analytical applications. Norbornene is a bicyclic compound. Norbornene polymers can be used in tissue engineering and drug release system.
|
|
/
|
| HY-D2651 | Cy5 HA MA (MW 50000) |
Cy5 HA MA (MW 50000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 50000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
|
|
/
|
| HY-D2649 | Cy5 HA MA (MW 5000) |
Cy5 HA MA (MW 5000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 5000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
|
|
/
|
| HY-D2681 | Cy7 HA MA (MW 3000) |
Cy7 HA MA (MW 3000) is a hyaluronic acid methacrylate labeled with CY7 (HY-D0825). Cy7 HA MA (MW 3000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 740/770 nm).
|
|
/
|
| HY-D2632 | Cy3 HA MA (MW 10000) |
Cy3 HA MA (MW 10000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 10000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
|
|
/
|
| HY-N0976 | 1,11b-Dihydro-11b-hydroxymedicarpin |
1,11b-Dihydro-11b-hydroxymedicarpin (11b-Hydroxy-11b,1-dihydromedicarpin) is a pterocarpan from Ononis viscosa subsp. breviflora is a Medicarpin derivative. Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathways. Medicarpin prevents arthritis in post-menopausal conditions by arresting the expansion of TH17 cells and pro-inflammatory cytokines. Medicarpin down-regulates pro-inflammatory cytokines like TNF-α, IL-6 and IL-17A, while up-regulates anti-inflammatory cytokine IL-10 in arthritis (CIA) model of mice.
|
|
/
|
| HY-D2633 | Cy3 HA MA (MW 50000) |
Cy3 HA MA (MW 50000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 50000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
|
|
/
|
| HY-126042S4 | (±)-Lisofylline-d4 |
(±)-Lisofylline-d4 ((±)-Lisophylline-d4) is deuterium labeled (±)-Lisofylline. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research.
|
|
/
|
| HY-158726 | Complex 3 |
Complex 3 is a fluorescent dithiocarbazate-copper complex with anticancer activity, which localizes to mitochondria. Complex 3 displays excitation/emission maxima of 455-495/535 nm, respectively. Complex 3 inhibits the growth of BxPC-3, AsPC-1, PANC-1, and WI38 pancreatic cancer cells with IC50 values of 0.74, 0.41, 0.62, and 2.06 µM, respectively. Complex 3 induces lipid peroxidation and mitochondrial rupture and shrinkage in AsPC-1 cells. Complex 3 also induces mitochondrial apoptosis and cytokine-cytokine receptor interaction dysfunction in AsPC-1 cells. Complex 3 reduces tumor volume in an AsPC-1 mouse xenograft model.
|
|
/
|
| HY-141432G | NX-1607 (GMP) |
|
/
|
|
| HY-D2650 | Cy5 HA MA (MW 10000) |
Cy5 HA MA (MW 10000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 10000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
|
|
/
|
| HY-D2634 | Cy3 HA MA (MW 100000) |
Cy3 HA MA (MW 100000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 100000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
|
|
/
|
| HY-D2648 | Cy5 HA MA (MW 3000) |
Cy5 HA MA (MW 3000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 3000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
|
|
/
|
| HY-D2631 | CY3 HA MA (MW 5000) |
Cy3 HA MA (MW 5000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 5000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
|
|
/
|
| HY-N6770 | Curvularin |
|
/
|
|
| HY-121892 | (Z)-KC02 |
(Z)-KC02 is an inhibitor of ABHD16A, the phosphatidylserine (PS) lipase that produces lyso-PS. Lysophosphatidylserine (lyso-PS) is a signaling lipid that regulates immune and neurological processes. It is associated with several neurological disorders such as retinitis pigmentosa and cataracts (PHARC). (Z)-KC02 depletes lyso-PS in lymphoblasts from PHARC subjects. (Z)-KC02 also reduces lyso-PS and lipopolysaccharide-induced cytokine production in macrophages and modulates lyso-PS metabolism in vivo.
|
|
/
|
| HY-N6878 | Cauloside D |
Cauloside D is a triterpene glycoside isolated from Caulophyllum robustum Max. Cauloside D exerts anti-inflammatory effects through the inhibition of expression of iNOS and proinflammatory cytokines.
|
|
/
|
| HY-P11355A | KRAS WT Peptide TFA |
KRAS WT Peptide TFA is the trifluoroacetate salt of KRAS WT Peptide (HY-P11355). KRAS WT Peptide is the normal sequence peptide of the Kirsten rat sarcoma virus (KRAS) gene without oncogenic mutations. KRAS WT Peptide can be used for the study of evaluating the specificity and safety of KRAS-targeted immunotherapies.
|
|
/
|
| HY-P991126 | Ciltistotug |
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.
Species: Human |
|
/
|
| HY-P991125 | Cenzestotug |
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.
Species: Human |
|
/
|
| HY-D1236 | Fluorescent brightener 71 |
Fluorescent brightener 71 (FB71) is an inhibitor targeting deubiquitinases UCHL5 and USP14, as well as a CD40 ligand. Fluorescent brightener 71 blocks enzymatic activity, induces apoptosis, inhibits cell growth and triggers reactive oxygen species production. Meanwhile, Fluorescent brightener 71 upregulates the expression of oxidative stress-related genes gpx-4 and sod-4, and reversibly increases the protein levels of UCHL5 and USP14 through a feedback response. Fluorescent brightener 71 inhibits the growth, movement and reproductive capacity of Caenorhabditis elegans, and also exhibits concentration-dependent toxic effects. Fluorescent brightener 71 can be applied to scientific research in related fields such as breast cancer.
|
|
/
|
| HY-122767 | Romurtide |
|
/
|
|
| HY-148775 | PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) |
PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can be used for studies related to bacterial wound infections and glioblastoma.
|
|
/
|
| HY-W415798 | Ac4GalNAlk |
Ac4GalNAlk is a weakly alkyne-labeled reagent for metabolic oligosaccharide engineering (MOE) that can be used to detect protein glycosylation. MOE reagents can be activated by cellular biosynthetic machinery into nucleotide sugars, which can be further traced through the introduction of glycoproteins in bioorthogonal chemistry. Ac4GalNAlk promotes nucleotide-sugar biosynthesis and increases bioorthogonal cell surface markers.
|
|
/
|
| HY-P992112 | Eliroptamig |
Eliroptamig is a multispecific antibody targeting albumin, folate receptor α (FOLR1) and cluster of differentiation 3 (CD3). Eliroptamig extends its half-life by binding to albumin, while targeting FOLR1 on tumor cells and activating T cells to achieve precise tumor killing.
Species: Human |
|
/
|
| HY-W145695 | Chitoheptaose |
Chitoheptaose is an orally active chitooligosaccharide (degree of polymerization = 7). Chitoheptaose can be extracted from the exoskeletons of crustaceans, such as the shells of crabs, shrimps and lobsters. Chitoheptaose reduces pro-inflammatory cytokines while increasing the levels of anti-inflammatory cytokines (decreasing the levels of pro-inflammatory cytokines IL-1β, IL-17A and IFN-γ, and increasing the level of the anti-inflammatory cytokine IL-10). Chitoheptaose possesses antioxidant, anti-inflammatory and anti-Apoptotic activities. Chitoheptaose improves cardiac parameters, alleviates myocarditis injury, and exerts cardioprotective effects in a rat model of myocarditis. Chitoheptaose can be used in studies related to myocarditis.
|
|
/
|
| HY-136512 | Streptazolin |
Streptazolin is an antibiotic. Streptazolin increases bacterial killing and elaboration of immunostimulatory cytokines by macrophages in vitro. Streptazolin stimulates the macrophage NF-κB pathway via PI3K signaling.
Source: Streptomyces viridochromogenes |
|
/
|
| HY-117123 | Convulxin |
Convulxin is a toxin found in a tropical rattlesnake. Convulxin stimulates platelet aggregation, and clusters GPVI to trigger Src family kinase activation, Fc receptor γ chain phosphorylation, and p72SYK signaling. Convulxin interacts with Dectin-2 to induce IL-10 production, activates monocytes to generate ROS and NLRP3 inflammasome-mediated IL-1β secretion, and induces mitochondrial ROS. Convulxin causes transient arterial blood pressure changes in dogs. Convulxin can be used for research related to coagulation.
Source: Crotalus durissus terrificus |
Glycoprotein VI
Src
Interleukin Related
Reactive Oxygen Species (ROS)
NOD-like Receptor (NLR)
Mitochondrial Metabolism
|
/
|
| HY-P2263A | KLD-12 TFA |
KLD-12 TFA is the TFA salt form of KLD-12 (HY-P2263). KLD-12 TFA is a self a 12-residue self-assembling peptide that is used in tissue-engineering. KLD-12 TFA combined with SDF-1 self-assembled polypeptide enhances chondrogenic differentiation of bone marrow stromal cells (BMSCs). KLD-12 TFA hydrogel can fill full-thickness osteochondral defects in situ and improve cartilage repair.
|
|
/
|
| HY-P991525 | 2141-V11 |
2141-V11 is an Fc-engineered agonistic antibody against human CD40 with selectively enhanced binding affinity for human FcγRIIB. 2141-V11 drives CD40 multimerization and agonistic signal transduction, activates dendritic cells, promotes antigen cross-presentation and CD8+ T cell priming, induces tertiary lymphoid structure formation, increases leukocyte infiltration, and mediates local and abscopal anti-tumor effects, systemic immune activation and immune memory. 2141-V11 exhibits extremely low systemic toxicity upon intratumoral or intravesical administration, with no dose-limiting toxicity observed at the tested intratumoral doses, whereas high-dose systemic administration induces thrombocytopenia and elevated transaminases. 2141-V11 can be used in research related to breast cancer, melanoma, BCG-unresponsive non-muscle invasive bladder cancer, and recurrent malignant glioma.
Species: Human |
|
/
|
| HY-P99704 | Licaminlimab |
Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation.
Species: Human |
|
/
|
| HY-P99825 | Relfovetmab |
|
/
|
|
| HY-P99431 | KY-1044 |
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response.
Species: Human |
|
/
|
| HY-P1828A | EGFRvIII peptide (PEPvIII) TFA |
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy.
|
|
/
|
| HY-P990901 | Aplitabart |
Aplitabart (IGM-8444) is a pentameric IgM death receptor 5 (DR5) agonist antibody with a KD of 85 nM and an apparent affinity of 11 pM. Aplitabart induces DR5 multimerization, thereby triggering cancer cell apoptosis via the extrinsic apoptotic pathway apoptosis. Aplitabart is applicable to cancer-related research such as colorectal cancer and gastric cancer.
Species: Human |
|
/
|
| HY-P10493A | NY-ESO-1 (157-165) peptide TFA |
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy.
|
|
/
|
| HY-158222 | Alginate Methacryloyl (MW 50000) |
Alginate Methacryloyl (MW 50000) is a methacryloyl alginate with potential for use as a tissue engineering scaffold and 3D printing ink. Alginate Methacryloyl (MW 50000) is biocompatible, non-immunogenic, has low toxicity and is capable of physical cross-linking with divalent cations such as calcium. Alginate Methacryloyl (MW 50000) needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc. |
|
/
|
| HY-P2263 | KLD-12 |
KLD-12 is a 12-residue self-assembling peptide that is used in tissue-engineering. KLD-12 combined with SDF-1 self-assembled polypeptide enhances chondrogenic differentiation of bone marrow stromal cells (BMSCs). KLD-12 hydrogel can fill full-thickness osteochondral defects in situ and improve cartilage repair.
|
|
/
|
| HY-W110542D | Poly(ethylene glycol) diacrylate (MW 1000) |
Poly(ethylene glycol) diacrylate (PEGDA) (MW 1000) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine.
|
|
/
|
| HY-D1005A2 | Poloxamer 105 (L35) |
Poloxamer 105 L35 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 1900 Da. Poloxamer 105 L35 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering.
|
|
/
|
| HY-P10089 | TREM-1 inhibitory peptide M3 |
TREM-1 inhibitory peptide M3 is a ligand-dependent TREM-1 antagonist. TREM-1 inhibitory peptide M3 can inhibit systemic and pulmonary pro-inflammatory cytokine and chemokine production and attenuate acute lung injury.
|
|
/
|
| HY-P99605 | Cinrebafusp alfa |
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research.
|
|
/
|
| HY-P990095 | Vonsetamig |
Vonsetamig (REGN5459) is a human bispecific antibody targeting BCMA and CD3. Vonsetamig triggers T-cell activation, induces plasma cell depletion, and triggers low-level cytokine release. Vonsetamig can be used for the research of relapsed/refractory multiple myeloma.
Species: Human |
|
/
|
| HY-P991336 | Ordastobart |
Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4+ and CD8+ T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer.
Species: Human |
|
/
|
| HY-158225 | Methacrylated Type I collagen |
Methacrylated Type I collagen (Col1MA) is a methacrylated tissue engineering scaffold material that retains the basic properties of natural collagen. Methacrylated Type I collagen needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc. |
|
/
|
| HY-W110542J | Poly(ethylene glycol) diacrylate (MW 700) |
Poly(ethylene glycol) diacrylate (PEGDA) (MW 700) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 700) mimics the extracellular matrix (ECM), providing support and growth space for cells.
|
|
/
|
| HY-B1648 | Ferric pyrophosphate |
Ferric pyrophosphate is an orally effective anti-inflammatory agent and iron fortifier. Ferric pyrophosphate downregulates the expression of colonic pro-inflammatory cytokines, modulates the intestinal flora, and corrects the dysbiosis associated with iron deficiency anemia (IDA). Ferric pyrophosphate can be used in studies related to iron deficiency anemia.
|
|
/
|
| HY-P99325 | Toralizumab |
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease.
Species: Human |
|
/
|
| HY-P99257 | Bleselumab |
|
/
|
|
| HY-P991201 | REGN-7257 |
REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases. Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).
Species: Human |
|
/
|
| HY-P10580A | Vasculotide TFA |
Vasculotide TFA is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide TFA binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury.
|
|
/
|
| HY-W145516 | Guar gum |
Guar gum is an orally active nonionic galactomannan polysaccharide. It is present in the endosperm of Cyamopsis tetragonolobus seeds. Guar gum reduces cholesterol levels, regulates body weight, and acts as a thickener and viscosity modifier by forming hydrogen-bonded aqueous solutions. It serves as a rate-controlling excipient in compound delivery systems, and finds applications in the food, tissue engineering, nanosensing and industrial fields.
|
|
/
|
| HY-P99304 | Lumretuzumab |
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer.
Species: Human |
|
/
|
| HY-P10580 | Vasculotide |
Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury.
|
|
/
|
| HY-P990083 | Tegoprubart |
Tegoprubart (AT-1501) is a CD40 ligand inhibitor (EC50=100 ng/mL) and immunosuppressant that selectively inhibits the CD40 ligand, a co-stimulatory molecule involved in T cell activation. Tegoprubart suppresses immune rejection, prevents rejection in animal transplantation models, and reduces cell-mediated and antibody-mediated immune responses to create a more immunotolerant environment. Tegoprubart preserves renal function when combined with Mycophenolate (HY-B0421) and Corticosteroids, and maintains graft function in preclinical studies. Tegoprubart is applicable to research related to kidney transplantation and kidney transplant rejection.
Species: Human |
|
/
|
| HY-P10493 | NY-ESO-1 (157-165) peptide |
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy.
|
|
/
|
| HY-158229 | Heparin Methacrylate |
Heparin Methacrylate (HepMA) is methacrylated heparin and is an ideal tissue engineering scaffold material and 3D printing bioink. Heparin Methacrylate needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc. |
|
/
|
| HY-W110542G | Poly(ethylene glycol) diacrylate (MW 6000) |
Poly(ethylene glycol) diacrylate (PEGDA) (MW 6000) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 6000) can be used as a building material for wound dressing hydrogels.
|
|
/
|
| HY-23119 | Sodium thiocyanate, GR, 99% |
Digestive System Disease
Prostate Cancer
Depression
Pain
Digestive System Inflammation
Rheumatoid Arthritis
|
/
|
|
| HY-P5558 | KLTWQELYQLKYKGI |
KLTWQELYQLKYKGI is a VEGF mimetic peptide designed based on the VEGF helix sequence 17-25, with the ability to activate VEGF receptors and exert pro-angiogenic biological activity. KLTWQELYQLKYKGI effectively promotes the attachment, spreading and proliferation of human umbilical vein endothelial cells. KLTWQELYQLKYKGI enhances the proliferation, migration and osteogenic differentiation of bone marrow stromal cells (BMSCs). KLTWQELYQLKYKGI synergistically accelerates angiogenesis and bone regeneration in rat cranial defect models. KLTWQELYQLKYKGI can be used for the research of brain tissue engineering and traumatic brain injury repair and biomaterials for bone tissue engineering and bone repair.
|
|
/
|
| HY-P9945 | Mepolizumab |
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma.
Species: Human |
|
/
|
| HY-D1005A6 | Poloxamer 124 (L44) |
Poloxamer 124 L44 is a block polymer of polyoxyethylene and polyoxypropylene and a hydrophobic surfactant. Poloxamer 124 L44 causes eye irritation and exhibits oral toxicity in albino rats with an LD50 of 5 g/kg. Poloxamer 124 L44 has reversible adverse effects on triglyceride and cholesterol transport in the lymphatic system of rats. Poloxamer 124 L44 can form thermoreversible hydrogels and is used as a food additive and as a drug delivery vehicle in cosmetics, pharmaceuticals, and tissue engineering[1][2][3].
|
|
/
|
| HY-P991097 | Pumitamig |
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
Species: Human |
|
/
|
| HY-W110584 | Carboxybetaine methacrylate |
Carboxybetaine methacrylate is an amphoteric ionic compound with excellent properties such as good hydrophilicity, antistatic property, and biocompatibility. Carboxybetaine methacrylate can be used to prepare tissue engineering scaffolds, drug carriers, and so on.
|
|
/
|
| HY-P99625 | Frexalimab |
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research.
Species: Human |
|
/
|
| HY-P990688 | Xaluritamig |
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.
Species: Human |
|
/
|
| HY-P10587 | Icotrokinra |
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.
|
|
/
|
| HY-P70609 | CD40L/CD154/TRAP Protein, Human (HEK293) |
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in human, cleaved into 2 chains of membrane form (1-261 a.a.) and soluble form (113-261 a.a.) which serves as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). GMP CD40L/CD154/TRAP Protein, Human (HEK293) has a total length of 149 amino acids (M113-L261), is expressed in HEK392 cells under GMP standard with tag free.
Species: Human; Source: HEK293 |
|
/
|
| HY-P71389 | TSLP Receptor Protein, Human (HEK293, His) |
TSLP Receptor Protein, a receptor for TSLP, forms a functional complex with IL7R, activating STAT3 and STAT5 for cell proliferation. It also activates JAK2, aiding in hematopoietic system development. TSLP Receptor forms a heterodimer with CRLF2 and IL7R, highlighting its role in intricate signaling pathways crucial for cellular responses and hematopoietic development. TSLP Receptor Protein, Human (HEK293, His) is the recombinant human-derived TSLP Receptor protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P78425 | CD40L/CD154/TRAP Trimer Protein, Human (HEK293, His-Flag) |
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in human, cleaved into 2 chains of membrane form (1-261 a.a.) and soluble form (113-261 a.a.) which serves as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). CD40L/CD154/TRAP Trimer Protein, Human (HEK293, His-Flag) is composed of a full-length monomer of 149 amino acids (M113-L261), is expressed in HEK392 cells with N-terminal His- and Flag-tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P79001 | Crlf1 Protein, Mouse (HEK293, His, solution) |
Crlf1 protein combines with CLCF1 to form an important neurotrophic cytokine involved in neuronal development. It plays a crucial role in the initiation and maintenance of lactation in neonatal mice and is associated with immune system regulation. Crlf1 Protein, Mouse (HEK293, His, solution) is the recombinant mouse-derived Crlf1 protein, expressed by HEK293 , with His labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P78271 | CD40L/CD154/TRAP Trimer Protein, Mouse (HEK293, Fc) |
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in mouse, cleaved into 2 chains of membrane form (1-260 a.a.) and soluble form (112-260 a.a.) which serves as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). CD40L/CD154/TRAP Trimer Protein, Mouse (HEK293, Fc) has a total length of 149 amino acids (M112-L260), is expressed in HEK392 cells with N-terminal hFc-tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P72122 | CD40L/CD154/TRAP Protein, Rabbit (His) |
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in Rabbit, cleaved into a soluble form, acts as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). CD40L/CD154/TRAP Protein, Rabbit (His) has a total length of 149 amino acids (M113-L261), is expressed in E. coli cells with N-terminal 6*His-tag.
Species: Rabbit; Source: E. coli |
|
/
|
| HY-P700842 | TSLP Receptor Protein, Cynomolgus (HEK293, His) |
TSLP Receptor protein is the receptor of TSLP and cooperates with IL7R to form a complex that activates STAT3 and STAT5 to stimulate cell proliferation. This receptor also activates JAK2, which is critical for the development of the hematopoietic system. TSLP Receptor Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived TSLP Receptor protein, expressed by HEK293 , with C-His labeled tag.
Species: Cynomolgus; Source: HEK293 |
|
/
|
| HY-P77583 | CYTL1 Protein, Human (HEK293, hFc) |
CYTL1 protein is specifically expressed in CD34+ hematopoietic cells, indicating that it exists selectively in this hematopoietic cell subpopulation. This targeted expression pattern suggests a potential role in maintaining or differentiating CD34+ cells, emphasizing the importance of CYTL1 in the complex molecular processes that control blood cell development. CYTL1 Protein, Human (HEK293, hFc) is the recombinant human-derived CYTL1 protein, expressed by HEK293 , with C-hFc labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P70794 | TSLP Receptor Protein, Human (HEK293, Fc) |
TSLP Receptor Protein, a receptor for TSLP, forms a functional complex with IL7R, activating STAT3 and STAT5 for cell proliferation. It also activates JAK2, aiding in hematopoietic system development. TSLP Receptor forms a heterodimer with CRLF2 and IL7R, highlighting its role in intricate signaling pathways crucial for cellular responses and hematopoietic development. TSLP Receptor Protein, Human (HEK293, Fc) is the recombinant human-derived TSLP Receptor protein, expressed by HEK293 , with C-hFc labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P78934 | CD40L/CD154/TRAP Protein, Human (Biotinylated, HEK293, Fc-Avi) |
CD40L/CD154/TRAP proteins stimulate T cell proliferation and cytokine production, acting as ligands for integrins and CD40 receptors to activate various cell-dependent effects such as B cell activation and NF-κ-B signaling. CD40L/CD154/TRAP Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived CD40L/CD154/TRAP protein, expressed by HEK293 , with N-hFc, N-Avi labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P71910 | CD40L/CD154/TRAP Protein, Human (C194W) |
CD40L/CD154/TRAP proteins stimulate T cell proliferation and cytokine production, acting as ligands for integrins and CD40 receptors to activate various cell-dependent effects such as B cell activation and NF-κ-B signaling. CD40L/CD154/TRAP Protein, Human (C194W) is the recombinant human-derived CD40L/CD154/TRAP protein, expressed by E. coli , with tag free. The total length of CD40L/CD154/TRAP Protein, Human (C194W) is 149 a.a., with molecular weight of ~16.3 kDa.
Species: Human; Source: E. coli |
|
/
|
| HY-P72907AF | Animal-Free CD40L/CD154/TRAP Protein, Human (His) |
CD40L/CD154/TRAP proteins stimulate T cell proliferation and cytokine production, acting as ligands for integrins and CD40 receptors to activate various cell-dependent effects such as B cell activation and NF-κ-B signaling. Animal-Free CD40L/CD154/TRAP Protein, Human (His) is the recombinant human-derived animal-FreeCD40L/CD154/TRAP protein, expressed by E. coli , with C-His labeled tag. This product is for cell culture use only.
Species: Human; Source: E. coli |
|
/
|
| HY-P70989 | TSLP Receptor Protein, Mouse (HEK293, His) |
Cytokine receptor-like factor 2 (Crlf2), also known as thymic stromal lymphopoietin (TSLP) receptor, is a receptor for TSLP. Crlf2 can forms a functional complex with TSLP and IL7RA, and overexpression of Crlf2 stimulates cell proliferation through activation of the JAK-STAT pathway. The expression of Crlf2 usually upregulates and mutated in populations of B-progenitor acute lymphoblastic leukemia (B-ALL). TSLP Receptor Protein, Mouse (HEK293, His) is the recombinant mouse-derived TSLP Receptor protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P76300 | CYTL1 Protein, Human (HEK293, mFc) |
CYTL1 protein is specifically expressed in CD34+ hematopoietic cells, indicating that it exists selectively in this hematopoietic cell subpopulation. This targeted expression pattern suggests a potential role in maintaining or differentiating CD34+ cells, emphasizing the importance of CYTL1 in the complex molecular processes that control blood cell development. CYTL1 Protein, Human (HEK293, mFc) is the recombinant human-derived CYTL1 protein, expressed by HEK293 , with C-mFc labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P705242 | TSLP Receptor Protein, Human (Biotinylated, HEK293, Fc-Avi) |
TSLP Receptor protein is the receptor for TSLP, forming a functional complex with IL7R, activating STAT3 and STAT5 to promote cell proliferation. It also activates JAK2, aiding in hematopoietic system development. The TSLP Receptor forms heterodimers with CRLF2 and IL7R, highlighting its role in a complex signaling pathway crucial for cellular responses and hematopoietic development. The TSLP Receptor Protein, Human (Biotinylated, HEK293, Fc-Avi) is a recombinant biotinylated TSLP Receptor protein expressed by HEK293 and tagged with C-Avi and C-hFc.
Species: Human; Source: HEK293 |
|
/
|
| HY-P70823 | TSLP Receptor Protein, Mouse (HEK293, Fc) |
Cytokine receptor-like factor 2 (Crlf2), also known as thymic stromal lymphopoietin (TSLP) receptor, is a receptor for TSLP. Crlf2 can forms a functional complex with TSLP and IL7RA, and overexpression of Crlf2 stimulates cell proliferation through activation of the JAK-STAT pathway. The expression of Crlf2 usually upregulates and mutated in populations of B-progenitor acute lymphoblastic leukemia (B-ALL). TSLP Receptor Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived TSLP Receptor protein, expressed by HEK293 , with C-hFc labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P72121 | CD40L/CD154/TRAP Protein, Rhesus macaque (His) |
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in Rhesus macaque, cleaved into 2 chains of membrane form (1-261 a.a.) and soluble form (113-261 a.a.) which serves as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). CD40L/CD154/TRAP Protein, Rhesus macaque (His) has a total length of 218 amino acids (V44-L261), is expressed in E. coli cells with N-terminal 6*His-tag.
Species: Rhesus Macaque; Source: E. coli |
|
/
|
| HY-P77584 | CYTL1 Protein, Mouse (HEK293, Fc) |
CYTL1 is a cytokine-like protein specifically expressed in bone marrow and cord blood mononuclear cells that bear the CD34 surface marker. CYTL1 exhibits specific expression in CD34+ hematopoietic cells, indicating its selective presence within this subset of cells involved in the regulation of hematopoiesis. CYTL1 regulates chondrogenesis and is required for the maintenance of cartilage homeostasis and, in addition, may act as a regulator of embryo implantation in early pregnancy. CYTL1 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CYTL1 protein, expressed by HEK293 , with C-hFc labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P705466 | CD40L/CD154/TRAP Trimer Protein, Mouse (HEK293, His-Flag) |
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P81113 | IL-10 Antibody (YA3521) |
|
/
|
|
| HY-P84952 | IL-10 Antibody (YA4644) |
|
/
|
|
| HY-P80328 | SOCS2 Antibody (YA072) |
SOCS2 Antibody (YA072) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SOCS2.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P86311 | IL-10 Antibody (YA6003) |
|
/
|
|
| HY-P811149 | CCL5 Antibody |
CCL5 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to CCL5.
Host: Rabbit; Reactivity: Human, Bovine |
|
/
|
| HY-P85219 | IL-10 Antibody (YA4911) |
|
/
|
|
| HY-P810855 | CD154 Antibody |
CD154 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to CD154.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P811287 | IL-9 Antibody |
|
/
|
|
| HY-P811796 | TRAP/CD40L Antibody (YA10267) |
TRAP/CD40L Antibody (YA10267) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to TRAP/CD40L.
Host: Rabbit; Reactivity: Human, Mouse |
|
/
|
| HY-P811796A | TRAP/CD40L Antibody (YA10267) (PBS only) |
TRAP/CD40L Antibody (YA10267) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to TRAP/CD40L.
Host: Rabbit; Reactivity: Human, Mouse |
|
/
|
| HY-P810383 | HVEM Antibody (YA9700) |
|
/
|
|
| HY-P85469 | SOCS-3 Antibody (YA5161) |
SOCS-3 Antibody (YA5161) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SOCS-3.
Host: Mouse; Reactivity: Human, Pig |
|
/
|
| HY-P86824 | CRLF3 Antibody (YA6517) |
CRLF3 Antibody (YA6517) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CRLF3.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P87452 | IL-9 Antibody (YA7139) |
|
/
|
|
| HY-K2033 | OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) |
MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology to achieve highly efficient nucleic acid(eg. pDNA、mRNA、sgRNA、siRNA) delivery into Jurkat cells. It is designed for in vitro transfection of Jurkat cells and is well suited for applications in immunotherapy, tumor immunology, and other immune cell-related research. |
|
/
|
| HY-K2034 | OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells) |
MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies. |
|
/
|
Targets/Pathways





































.jpg)













































































































































